#USA #San Diego #Crenessity #Neurocrine Biosciences #INGREZZA

Neurocrine Biosciences Reports First Quarter 2025 Financial Results

In a recent announcement, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) revealed its financial performance for the first quarter of 2025, culminating on March 31. The quarter showcased impressive growth metrics, particularly in its neurology-focused product lines. The company reaffirms its financial forecast for the year, highlighting its commitment to sustaining innovation in neuropsychiatric and neurological treatments.

Financial Highlights

Neurocrine's net product sales for INGREZZA, its flagship medication for tardive dyskinesia, reached an impressive $545 million during the first quarter of 2025. This figure marks an 8% increase compared to the same period in 2024, indicating strong underlying patient demand driven by a significant number of new patient starts. The company reiterated its annual sales guidance for INGREZZA, maintaining an expected range between $2.5 billion and $2.6 billion for 2025.

Additionally, the sales for CRENESSITY, a new product targeted at managing congenital adrenal hyperplasia, amounted to $14.5 million. This product's initial launch has shown promising reception within its target patient community, with substantial reimbursement coverage already in place.

Strategic Developments

Neurocrine has recently initiated several critical clinical programs aimed at expanding its pipeline. Notably, the Phase 3 registrational studies for osavampator, a potential first-in-class treatment for major depressive disorders, and NBI-'568, aimed at addressing schizophrenia, are pivotal steps in enhancing Neurocrine's therapeutic offerings. These initiatives reflect the company's strategy to deliver on its commitments to growth and innovation in neuroscience.

Dr. Kyle W. Gano, CEO of Neurocrine Biosciences, expressed optimism regarding the ongoing momentum, particularly through the successful launch and patient engagement efforts. He noted, "This strong performance gives us good momentum heading into the rest of the year."

Recent Corporate Changes

In a sign of its expanding leadership, Neurocrine appointed Sanjay Keswani, M.D., as the Chief Medical Officer, effective June 2, 2025. This addition to the executive team signals a commitment to maintaining high standards in clinical development and patient care.

Financial Insights

Examining the overall financial health of Neurocrine, the company reported total revenues of $572.6 million for the quarter, a significant rise from $515.3 million the previous year. This increase can be traced back to both product sales growth and rising interest in collaborative partnerships within the healthcare sector.

However, it is noteworthy that the company's GAAP net income for Q1 2025 stood at $7.9 million, a decline from $43.4 million noted in Q1 2024. This drop is credited to increased expenses related to research and development, as well as the costs associated with the expanded market presence for INGREZZA and the new launch of CRENESSITY.

On the operational front, Neurocrine also completed a $300 million accelerated share repurchase program and announced a new share repurchase initiative worth $500 million, showcasing its strategic focus on enhancing shareholder value.

Conclusion

As Neurocrine Biosciences continues to innovate and expand its market presence, the first quarter of 2025 establishes a foundation for the company's future growth. With its reaffirmed financial guidance and recent clinical advancements, Neurocrine positions itself as a leader in addressing critical neurological disorders. Stakeholders and industry observers alike will be keenly watching how these developments unfold in the months ahead, particularly in light of the upcoming phase 3 trials that could significantly influence the company's trajectory.

For additional details and the latest updates, stakeholders can tune into the live conference call hosted by Neurocrine, scheduled for today at 4:30 PM ET or access the replay shortly after through the company's website.